In one trial of an anti-mesothelin T-cell receptor fusion construct for mesothelin-expressing tumors, grade 3 or higher pneumonitis was seen in 16% of patients as well as 3 grade 5 events related to the T-cell therapy (bronchoalveolar hemorrhage, pneumonitis, and respiratory failure in the setting of CRS) [87]. Here, MSLN is linked to pneumonitis.